title: [Effect of drugs for osteoporosis on cardiovascular diseases and effect of cardio vascular drugs on osteoporosis].
abstract: Osteoporosis and cardiovascular diseases are epidemiologically associated. Calcification phenomena of atherosclerotic plaque involve cytokines and growth factors also involved in bone remodeling. Drugs given for either of these two conditions could act on these mechanisms. Can osteoporosis drugs have an influence on the occurrence of cardiovascular events? Conversely, can the treatment of hypertension alter the course of osteoporosis? It is possible that administration of high doses of calcium (1g/day) in patients who already have important dietary intake can increase the risk of myocardial infarction. Epidemiological studies show links between low serum vitamin D levels and cardiovascular disease but interventional studies show that vitamin D administration in moderately deficient subjects vitamin D does not prevent the occurrence of cardiovascular events. Cohort studies show a beneficial effect of beta-blockers and thiazides administered to hypertensive patients: they reduce by 20% risk of fracture of the proximal femur. Should we focus on these anti-hypertensive treatments for our patients with osteoporosis?
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France. Electronic address: laroche.m@chu-toulouse.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Laroche
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Degboe
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Hubert
authors.initials: H
authors.lastname: Blain
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Breuil
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Bernard
authors.initials: B
authors.lastname: Cortet
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Sutter
authors.affiliation: CHU Purpan, hôpital Pierre-Paul-Riquet, centre de rhumatologie, 1, place du Dr-Baylac, 31059 Toulouse cedex, France.
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002118:Calcium / Q000009:adverse effects / Q000493:pharmacokinetics; D002136:Calcium, Dietary / Q000493:pharmacokinetics; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D000069448:Denosumab / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced / Q000150:complications; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D049993:Sodium Chloride Symporter Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D019379:Teriparatide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D014807:Vitamin D / Q000493:pharmacokinetics / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D002317:Cardiovascular Agents; D004164:Diphosphonates; D049993:Sodium Chloride Symporter Inhibitors; D019379:Teriparatide; D014807:Vitamin D; D000069448:Denosumab; D002118:Calcium